Genomics and microbiome intelligence for high-volume programs
From the sequenced genome to a decision that stands up to review.
Once a program sequences hundreds or thousands of genomes a month, producing data stops being the hard part. Turning it into evidence that is traceable, comparable and analytically sound enough for decisions with clinical, public-health or environmental consequences is.
Thousands of samples produce more results than any team can read with judgement. Without a layer that prioritises and documents, quality depends on who is reviewing that day.
Every batch changes the method without anyone deciding it.
References, versions and annotators drift between deliveries, and technical differences end up mistaken for biological findings.
Insight without provenance cannot carry a decision.
A result that cannot be rerun or audited is of no use to a clinical committee, a health authority or an external reviewer.
Nexalel turns that flow into evidence: analyses with frozen methods, comparisons that separate signal from artefact, and packages a third party can verify and run again.
What we deliver
Three outcomes a program can demand
Reproduce, compare and substantiate, with public cases you can examine today. Scope and feasibility are agreed for every study before a single file is processed.
Assess what can be compared and which differences prevent a conclusion.
View deliverable and scope
A processed cohort, a declared comparison and an explicit list of what the comparison does not allow you to conclude.
Available
The public 16S atlas can be consulted. Comparing a new cohort requires a compatibility assessment and an agreed method; it is not a self-service capability.
A report that connects each conclusion to its evidence and its limits.
View deliverable and scope
A report that separates observation, inference and interpretation, with the intended use stated in writing.
Available
The format is published and can be downloaded from the public microbiome case.
Who we serve
Built for teams that sequence at scale
National programs, hospitals, laboratories, industry and funders share the same problem with different urgency. Pick the starting point that looks most like yours.